Leading investments into growth-stage technology and healthcare companies, William Staveacre brings operating and board experience to capital allocation decisions. He evaluates revenue model durability, unit economics, and founder-market fit to prioritize deals that can scale to exit via trade sale or IPO. Active in LP fundraising and syndicate formation, he contributes to portfolio governance and go-to-market execution. Prior roles encompass operating management and investment leadership, providing cross-functional insight into product, sales and financial operations.
Leading investments into growth-stage technology and healthcare companies, William Staveacre brings operating and board experience to capital allocation decisions. He evaluates revenue model durability, unit economics, and founder-market fit to prioritize deals that can scale to exit via trade sale or IPO. Active in LP fundraising and syndicate formation, he contributes to portfolio governance and go-to-market execution. Prior roles encompass operating management and investment leadership, providing cross-functional insight into product, sales and financial operations.
Focuses on growth-stage technology and healthcare companies, prioritizing repeatable revenue models, strong unit economics and clear founder-market fit. Allocates capital with a staged, milestone-driven approach that balances runway extension and go-to-market scaling, targeting exits via trade sale or IPO over a 3–7 year horizon. Employs active board engagement and operating partnership to de-risk commercial execution, leaning toward B2B SaaS, digital health and platform-enabled services. Investment decisions emphasize differentiated product defensibility, measurable growth efficiency and founder alignment; downside risk is managed through conviction-weighted positions and syndicate co-investment.
Focuses on growth-stage technology and healthcare companies, prioritizing repeatable revenue models, strong unit economics and clear founder-market fit. Allocates capital with a staged, milestone-driven approach that balances runway extension and go-to-market scaling, targeting exits via trade sale or IPO over a 3–7 year horizon. Employs active board engagement and operating partnership to de-risk commercial execution, leaning toward B2B SaaS, digital health and platform-enabled services. Investment decisions emphasize differentiated product defensibility, measurable growth efficiency and founder alignment; downside risk is managed through conviction-weighted positions and syndicate co-investment.
| Trades 7061 | Longs Won 2226/7061 31% | Profit Factor 1.62 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $115,487.46 |
| Average Win $43,042.25 | Best Trade (Sep 30) $4.67M | Sharpe Ratio -32.63 |
| Average Loss -$12,211.97 | Worst Trade (Dec 31) -$4.38M | Z-Score 0.77 (55.99%) |
| Commissions $0 | Avg. Trade Length 4m 1w 6d | Expectancy $5,207.08 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 30,303 | 27,273 | 24,242 | 21,212 | 18,182 | 15,152 | 12,121 | 9,091 | 6,061 | 3,030 |